IL37 and inflammatory bowel disease: Wang et al. [104] tested the hypothesis that IL-23 suppresses CLDN8 expression through miR-223 to mediate IBD, by inhibiting miR-233 expression via the intraperitoneal administration of antagomir-223 (dose: 7.5 mg/kg, prepared as 3 mg/mL in PBS, dosed for three successive days 24 h after TNBS administration) in the TNBS-colitis model.